Specimen:
Collect
- One SST
Also Acceptable:
- One Blue Top (Na Citrate)
- One Green Top (Li Heparin)
- One Green Top (Na Heparin)
- One Lavender (EDTA)
- One Pink Top (EDTA)
- One Red Top
Submit
- 1 mL (Min:0.5 mL) Serum . Submit Refrigerated. Submit in a Standard Transport Tube.
Also Acceptable:
- 1 mL (Min:0.5 mL) Plasma . Submit Refrigerated. Submit in a Standard Transport Tube.
Special Handling
- For patients receiving therapy with high biotin doses (>5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
- Minimize air exposure
- Due to special analytical handling this test can not be added to previously drawn specimens.
Rejection Criteria
- Grossly Hemolyzed Samples
Stability
Ambient: 3 Day(s); Refrigerated: 3 Week(s); Frozen: 3 Month(s); Incubated: Unacceptable
Methodology
- Electrochemiluminescence Immunoassay, Sandwich (ECLIA)
Performed
Mon-Fri
Reported
1-3 Day(s)
CPT Codes
- 86803
Interpretive Data
General Reference Range : negative
ANTI-HCV INTERPRETIVE NOTES:
NEGATIVE: NO SEROLOGIC EVIDENCE OF CURRENT OR PAST HEPATITIS C VIRUS INFECTION.
POSITIVE: IF ANTI-HCV POSITIVE IS A TRUE POSITIVE, THIS IS CONSISTENT WITH CURRENT OR PAST HEPATITIS C VIRUS INFECTION. AT LEAST 70% OF THESE PATIENTS ARE OR WILL BECOME CHRONIC CARRIERS OF HEPATITIS C, WITH RISK OF CHRONIC ACTIVE HEPATITIS, CIRRHOSIS, AND/OR HEPATOMA. ANTI-HCV IS NOT PROTECTIVE. PATIENTS POSITIVE FOR ANTI-HCV SHOULD BE CONSIDERED INFECTIVE FOR HEPATITIS C. TEST FOR HCV RNA TO IDENTIFY CURRENT INFECTION.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
ANTI-HCV INTERPRETIVE NOTES:
NEGATIVE: NO SEROLOGIC EVIDENCE OF CURRENT OR PAST HEPATITIS C VIRUS INFECTION.
POSITIVE: IF ANTI-HCV POSITIVE IS A TRUE POSITIVE, THIS IS CONSISTENT WITH CURRENT OR PAST HEPATITIS C VIRUS INFECTION. AT LEAST 70% OF THESE PATIENTS ARE OR WILL BECOME CHRONIC CARRIERS OF HEPATITIS C, WITH RISK OF CHRONIC ACTIVE HEPATITIS, CIRRHOSIS, AND/OR HEPATOMA. ANTI-HCV IS NOT PROTECTIVE. PATIENTS POSITIVE FOR ANTI-HCV SHOULD BE CONSIDERED INFECTIVE FOR HEPATITIS C. TEST FOR HCV RNA TO IDENTIFY CURRENT INFECTION.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Components
- 2304 - ANTI-HCV
Last Updated: May 11, 2025 @ 9:13 am
Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date. Updated test information can only be guaranteed by using this website.
